It is also worth remembering that, although most AR-focused drug discovery programs are aimed at tackling PCa, receptor modulators may also be of value for the treatment of emerging other conditions such as androgenic alopecia, breast cancer, melanoma, medulloblastoma, androgen insensitivity syndromes or SBMA. Here, AR is linked to breast cancer.